Citation: | Jikai He, Jiaqi Jia, Wenhao Qu, Lizhou Jia, Wei Zhao. The function and regulatory mechanism of B cells in tumor immunity[J]. Blood&Genomics, 2022, 6(2): 103-113. doi: 10.46701/BG.2022022022031 |
[1] |
Lianyuan T, Dianrong X, Chunhui Y, et al. The predictive value and role of stromal tumor-infiltrating lymphocytes in pancreatic ductal adenocarcinoma (PDAC)[J]. Cancer Biol Ther, 2018, 19(4): 296−305. doi: 10.1080/15384047.2017.1416932
|
[2] |
Li Q, Teitz-Tennenbaum S, Donald EJ, et al. In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy[J]. J Immunol, 2009, 183(5): 3195−3203. doi: 10.4049/jimmunol.0803773
|
[3] |
Shen S, Xu Z, Qian X, et al. Autogeneic rna-electroporated CD40-ligand activated b-cells from hepatocellular carcinoma patients induce CD8+ T-cell responses ex vivo[J]. Exp Oncol, 2007, 29(2): 137–143.
|
[4] |
Rosser EC, Mauri C. Regulatory B cells: origin, phenotype, and function[J]. Immunity, 2015, 42(4): 607−612. doi: 10.1016/j.immuni.2015.04.005
|
[5] |
Mahmoud SM, Lee AH, Paish EC, et al. The prognostic significance of B lymphocytes in invasive carcinoma of the breast[J]. Breast Cancer Res Treat, 2012, 132(2): 545−553. doi: 10.1007/s10549-011-1620-1
|
[6] |
Qin Y, Peng F, Ai L, et al. Tumor-infiltrating B cells as a favorable prognostic biomarker in breast cancer: a systematic review and meta-analysis[J]. Cancer Cell Int, 2021, 21(1): 310. doi: 10.1186/s12935-021-02004-9
|
[7] |
Schalper KA, Brown J, Carvajal-Hausdorf D, et al. Objective measurement and clinical significance of TILs in non-small cell lung cancer[J]. J Natl Cancer Inst, 2015, 107(3): dju435. doi: 10.1093/jnci/dju435
|
[8] |
Fridman WH, Petitprez F, Meylan M, et al. B cells and cancer: to B or not to B?[J]. J Exp Med, 2021, 218(1): e20200851. doi: 10.1084/jem.20200851
|
[9] |
Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression[J]. Cancer Res, 2019, 79(18): 4557−4566. doi: 10.1158/0008-5472.Can-18-3962
|
[10] |
Xie Y, Xie F, Zhang L, et al. Targeted anti-tumor immunotherapy using tumor infiltrating cells[J]. Adv Sci (Weinh), 2021, 8(22): e2101672. doi: 10.1002/advs.202101672
|
[11] |
Ager A, May MJ. Understanding high endothelial venules: lessons for cancer immunology[J]. Oncoimmunology, 2015, 4(6): e1008791. doi: 10.1080/2162402x.2015.1008791
|
[12] |
Burger JA, Wiestner A. Targeting B cell receptor signalling in cancer: preclinical and clinical advances[J]. Nat Rev Cancer, 2018, 18(3): 148−167. doi: 10.1038/nrc.2017.121
|
[13] |
Melo-Gonzalez F, Kammoun H, Evren E, et al. Antigen-presenting ILC3 regulate T cell-dependent IgA responses to colonic mucosal bacteria[J]. J Exp Med, 2019, 216(4): 728−742. doi: 10.1084/jem.20180871
|
[14] |
Wang SS, Liu W, Ly D, et al. Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer[J]. Cell Mol Immunol, 2019, 16(1): 6−18. doi: 10.1038/s41423-018-0027-x
|
[15] |
Michaud D, Steward CR, Mirlekar B, et al. Regulatory B cells in cancer[J]. Immunol Rev, 2021, 299(1): 74−92. doi: 10.1111/imr.12939
|
[16] |
Sautès-Fridman C, Verneau J, Sun CM, et al. Tertiary lymphoid structures and B cells: clinical impact and therapeutic modulation in cancer[J]. Semin Immunol, 2020, 48: 101406. doi: 10.1016/j.smim.2020.101406
|
[17] |
Jia L, Wang T, Zhao Y, et al. Single-cell profiling of infiltrating B cells and tertiary lymphoid structures in the TME of gastric adenocarcinomas[J]. Oncoimmunology, 2021, 10(1): 1969767. doi: 10.1080/2162402x.2021.1969767
|
[18] |
Chiaruttini G, Mele S, Opzoomer J, et al. B cells and the humoral response in melanoma: the overlooked players of the tumor microenvironment[J]. Oncoimmunology, 2017, 6(4): e1294296. doi: 10.1080/2162402x.2017.1294296
|
[19] |
Reuschenbach M, von Knebel Doeberitz M, Wentzensen N. A systematic review of humoral immune responses against tumor antigens[J]. Cancer Immunol Immunother, 2009, 58(10): 1535−1544. doi: 10.1007/s00262-009-0733-4
|
[20] |
Guillem EB, Sampsel JW. Antitumor-associated antigens IgGs: dual positive and negative potential effects for cancer therapy[J]. Adv Exp Med Biol, 2006, 587: 341−374. doi: 10.1007/978-1-4020-5133-3_26
|
[21] |
Oh JE, Iijima N, Song E, et al. Migrant memory B cells secrete luminal antibody in the vagina[J]. Nature, 2019, 571(7763): 122−126. doi: 10.1038/s41586-019-1285-1
|
[22] |
Talebian Yazdi M, Loof NM, Franken KL, et al. Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma[J]. Cancer Immunol Immunother, 2015, 64(9): 1109−1121. doi: 10.1007/s00262-015-1716-2
|
[23] |
Kurtenkov O, Innos K, Sergejev B, et al. The Thomsen-Friedenreich antigen-specific antibody signatures in patients with breast cancer[J]. Biomed Res Int, 2018, 2018: 9579828. doi: 10.1155/2018/9579828
|
[24] |
Avalos AM, Ploegh HL. Early BCR events and antigen capture, processing, and loading on MHC class Ⅱ on B cells[J]. Front Immunol, 2014, 5: 92. doi: 10.3389/fimmu.2014.00092
|
[25] |
Phan TG, Grigorova I, Okada T, et al. Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells[J]. Nat Immunol, 2007, 8(9): 992−1000. doi: 10.1038/ni1494
|
[26] |
Mizoguchi A, Mizoguchi E, Takedatsu H, et al. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation[J]. Immunity, 2002, 16(2): 219−230. doi: 10.1016/s1074-7613(02)00274-1
|
[27] |
Moore DK, Loxton AG. Regulatory B lymphocytes: development and modulation of the host immune response during disease[J]. Immunotherapy, 2019, 11(8): 691−704. doi: 10.2217/imt-2018-0185
|
[28] |
Matsumoto M, Baba A, Yokota T, et al. Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation[J]. Immunity, 2014, 41(6): 1040−1051. doi: 10.1016/j.immuni.2014.10.016
|
[29] |
Chen Z, Zhu Y, Du R, et al. Role of regulatory B cells in the progression of cervical cancer[J]. Mediators Inflamm, 2019, 2019: 6519427. doi: 10.1155/2019/6519427
|
[30] |
Wang X, Li J, Lu C, et al. IL-10-producing B cells in differentiated thyroid cancer suppress the effector function of T cells but improve their survival upon activation[J]. Exp Cell Res, 2019, 376(2): 192−197. doi: 10.1016/j.yexcr.2019.01.021
|
[31] |
Shen P, Roch T, Lampropoulou V, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases[J]. Nature, 2014, 507(7492): 366−370. doi: 10.1038/nature12979
|
[32] |
Sakkas LI, Mavropoulos A, Perricone C, et al. IL-35: a new immunomodulator in autoimmune rheumatic diseases[J]. Immunol Res, 2018, 66(3): 305−312. doi: 10.1007/s12026-018-8998-3
|
[33] |
Tavakolpour S, Kheiry F, Mirsafaei HS, et al. The possible role of interleukin-35 and its therapeutic potential in pemphigus[J]. Int Immunopharmacol, 2017, 42: 11−17. doi: 10.1016/j.intimp.2016.11.005
|
[34] |
Egwuagu CE, Yu CR, Sun L, et al. Interleukin 35: critical regulator of immunity and lymphocyte-mediated diseases[J]. Cytokine Growth Factor Rev, 2015, 26(5): 587−593. doi: 10.1016/j.cytogfr.2015.07.013
|
[35] |
Zhu Z, Zhang Y, Ye J, et al. IL-35 promoted STAT3 phosphorylation and IL-10 production in B cells, but its production was reduced in patients with coronary artery diseases[J]. Hum Immunol, 2018, 79(12): 869−875. doi: 10.1016/j.humimm.2018.10.009
|
[36] |
Kao JY, Gong Y, Chen CM, et al. Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine[J]. J Immunol, 2003, 170(7): 3806−3811. doi: 10.4049/jimmunol.170.7.3806
|
[37] |
Kessel A, Haj T, Peri R, et al. Human CD19+CD25high B regulatory cells suppress proliferation of CD4+ T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells[J]. Autoimmun Rev, 2012, 11(9): 670−677. doi: 10.1016/j.autrev.2011.11.018
|
[38] |
Cui C, Wang J, Fagerberg E, et al. Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses[J]. Cell, 2021, 184(25): 6101−6118.e13. doi: 10.1016/j.cell.2021.11.007
|
[39] |
Zhu W, Germain C, Liu Z, et al. A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4+ T cell receptor repertoire clonality[J]. Oncoimmunology, 2015, 4(12): e1051922. doi: 10.1080/2162402x.2015.1051922
|
[40] |
Eerola AK, Soini Y, Pääkkö P. Tumour infiltrating lymphocytes in relation to tumour angiogenesis, apoptosis and prognosis in patients with large cell lung carcinoma[J]. Lung cancer, 1999, 26(2): 73−83. doi: 10.1016/s0169-5002(99)00072-0
|
[41] |
Liu J, Wang H, Yu Q, et al. RETRACTED: aberrant frequency of IL-10-producing B cells and its association with Treg and MDSC cells in Non Small Cell Lung Carcinoma patients[J]. Hum Immunol, 2016, 77(1): 84−89. doi: 10.1016/j.humimm.2015.10.015
|
[42] |
Garaud S, Buisseret L, Solinas C, et al. Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer[J]. JCI insight, 2019, 5(18): e129641. doi: 10.1172/jci.insight.129641
|
[43] |
Keren L, Bosse M, Marquez D, et al. A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging[J]. Cell, 2018, 174(6): 1373−1387.e19. doi: 10.1016/j.cell.2018.08.039
|
[44] |
Seow DYB, Yeong JPS, Lim JX, et al. Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers[J]. Breast Cancer Res Treat, 2020, 180(2): 369−377. doi: 10.1007/s10549-020-05548-y
|
[45] |
Guan H, Lan Y, Wan Y, et al. PD-L1 mediated the differentiation of tumor-infiltrating CD19+ B lymphocytes and T cells in Invasive breast cancer[J]. Oncoimmunology, 2016, 5(2): e1075112. doi: 10.1080/2162402x.2015.1075112
|
[46] |
Delvecchio FR, Goulart MR, Fincham REA, et al. B cells in pancreatic cancer stroma[J]. World J Gastroenterol, 2022, 28(11): 1088−1101. doi: 10.3748/wjg.v28.i11.1088
|
[47] |
Gunderson AJ, Kaneda MM, Tsujikawa T, et al. Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer[J]. Cancer Discov, 2016, 6(3): 270−285. doi: 10.1158/2159-8290.Cd-15-0827
|
[48] |
Lee KE, Spata M, Bayne LJ, et al. Hif1a deletion reveals pro-neoplastic function of B cells in pancreatic neoplasia[J]. Cancer Discov, 2016, 6(3): 256−269. doi: 10.1158/2159-8290.Cd-15-0822
|
[49] |
Li S, Mirlekar B, Johnson BM, et al. STING-induced regulatory B cells compromise NK function in cancer immunity[J]. Nature, 2022, 610(7931): 373−380. doi: 10.1038/s41586-022-05254-3
|
[50] |
Castino GF, Cortese N, Capretti G, et al. Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma[J]. Oncoimmunology, 2016, 5(4): e1085147. doi: 10.1080/2162402x.2015.1085147
|
[51] |
Meshcheryakova A, Tamandl D, Bajna E, et al. B cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancer[J]. PLoS One, 2014, 9(6): e99008. doi: 10.1371/journal.pone.0099008
|
[52] |
Shen T, Liu JL, Wang CY, et al. Targeting Erbin in B cells for therapy of lung metastasis of colorectal cancer[J]. Signal Transduct Target Ther, 2021, 6(1): 115. doi: 10.1038/s41392-021-00501-x
|
[53] |
Berntsson J, Nodin B, Eberhard J, et al. Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer[J]. Int J Cancer, 2016, 139(5): 1129−1139. doi: 10.1002/ijc.30138
|
[54] |
Edin S, Kaprio T, Hagström J, et al. The prognostic importance of CD20+ B lymphocytes in colorectal cancer and the relation to other immune cell subsets[J]. Sci Rep, 2019, 9(1): 19997. doi: 10.1038/s41598-019-56441-8
|
[55] |
He W, Wang B, He J, et al. SSR4 as a prognostic biomarker and related with immune infiltration cells in colon adenocarcinoma[J]. Expert Rev Mol Diagn, 2022, 22(2): 223−231. doi: 10.1080/14737159.2022.2019015
|
[56] |
Henriksen JR, Nederby L, Donskov F, et al. Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy[J]. J Ovarian Res, 2020, 13(1): 59. doi: 10.1186/s13048-020-00661-4
|
[57] |
Biswas S, Mandal G, Payne KK, et al. IgA transcytosis and antigen recognition govern ovarian cancer immunity[J]. Nature, 2021, 591(7850): 464−470. doi: 10.1038/s41586-020-03144-0
|
[58] |
Kroeger DR, Milne K, Nelson BH. Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic t-cell responses, and superior prognosis in ovarian cancer[J]. Clin Cancer Res, 2016, 22(12): 3005−3015. doi: 10.1158/1078-0432.Ccr-15-2762
|
[59] |
Lichtman A. The ABCs of ovarian cancer immunology: IgA, B cells, and CTLs[J]. Sci Immunol, 2021, 6(57): eabh3184. doi: 10.1126/sciimmunol.abh3184
|
[60] |
Lundgren S, Berntsson J, Nodin B, et al. Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer[J]. J Ovarian Res, 2016, 9: 21. doi: 10.1186/s13048-016-0232-0
|
[61] |
Yang C, Lee H, Jove V, et al. Prognostic significance of B-cells and pSTAT3 in patients with ovarian cancer[J]. PLoS One, 2013, 8(1): e54029. doi: 10.1371/journal.pone.0054029
|
[62] |
Ni Z, Xing D, Zhang T, et al. Tumor-infiltrating B cell is associated with the control of progression of gastric cancer[J]. Immunol Res, 2021, 69(1): 43−52. doi: 10.1007/s12026-020-09167-z
|
[63] |
Wang WW, Yuan XL, Chen H, et al. CD19+CD24hiCD38hiBregs involved in downregulate helper T cells and upregulate regulatory T cells in gastric cancer[J]. Oncotarget, 2015, 6(32): 33486−33499. doi: 10.18632/oncotarget.5588
|
[64] |
Garnelo M, Tan A, Her Z, et al. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma[J]. Gut, 2017, 66(2): 342−351. doi: 10.1136/gutjnl-2015-310814
|
[65] |
Brunner SM, Itzel T, Rubner C, et al. Tumor-infiltrating B cells producing antitumor active immunoglobulins in resected HCC prolong patient survival[J]. Oncotarget, 2017, 8(41): 71002−71011. doi: 10.18632/oncotarget.20238
|
[66] |
Shao Y, Lo CM, Ling CC, et al. Regulatory B cells accelerate hepatocellular carcinoma progression via CD40/CD154 signaling pathway[J]. Cancer Lett, 2014, 355(2): 264−272. doi: 10.1016/j.canlet.2014.09.026
|
[67] |
Xue H, Lin F, Tan H, et al. Overrepresentation of IL-10-expressing B cells suppresses cytotoxic CD4+ T cell activity in HBV-induced hepatocellular carcinoma[J]. PLoS One, 2016, 11(5): e0154815. doi: 10.1371/journal.pone.0154815
|
[68] |
Erdag G, Schaefer JT, Smolkin ME, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma[J]. Cancer Res, 2012, 72(5): 1070−1080. doi: 10.1158/0008-5472.Can-11-3218
|
[69] |
Garg K, Maurer M, Griss J, et al. Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome[J]. Hum Pathol, 2016, 54: 157−164. doi: 10.1016/j.humpath.2016.03.022
|
[70] |
Gilbert AE, Karagiannis P, Dodev T, et al. Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies[J]. PLoS One, 2011, 6(4): e19330. doi: 10.1371/journal.pone.0019330
|
[71] |
Bosisio FM, Wilmott JS, Volders N, et al. Plasma cells in primary melanoma. Prognostic significance and possible role of IgA[J]. Mod Pathol, 2016, 29(4): 347−358. doi: 10.1038/modpathol.2016.28
|
[72] |
Somasundaram R, Zhang G, Fukunaga-Kalabis M, et al. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance[J]. Nat Commun, 2017, 8(1): 607. doi: 10.1038/s41467-017-00452-4
|
[73] |
Kobayashi T, Oishi K, Okamura A, et al. Regulatory B1a cells suppress melanoma tumor immunity via IL-10 production and inhibiting T helper type 1 cytokine production in tumor-infiltrating CD8+ T cells[J]. J Invest Dermatol, 2019, 139(7): 1535−1544.e1. doi: 10.1016/j.jid.2019.02.016
|
[74] |
Svensson MC, Warfvinge CF, Fristedt R, et al. The integrative clinical impact of tumor-infiltrating T lymphocytes and NK cells in relation to B lymphocyte and plasma cell density in esophageal and gastric adenocarcinoma[J]. Oncotarget, 2017, 8(42): 72108−72126. doi: 10.18632/oncotarget.19437
|
[75] |
Wang Z, Cheng Z, Lu S, et al. Characterization of the intra-tumoral B cell immunoglobulin repertoire is of prognostic value for esophageal squamous cell carcinoma[J]. Front Immunol, 2022, 13: 896627. doi: 10.3389/fimmu.2022.896627
|
[76] |
Lu L, Weng C, Mao H, et al. IL-17A promotes migration and tumor killing capability of B cells in esophageal squamous cell carcinoma[J]. Oncotarget, 2016, 7(16): 21853−21864. doi: 10.18632/oncotarget.7869
|
[77] |
Kam NW, Wu KC, Dai W, et al. Peritumoral B cells drive proangiogenic responses in HMGB1-enriched esophageal squamous cell carcinoma[J]. Angiogenesis, 2022, 25(2): 181−203. doi: 10.1007/s10456-021-09819-0
|
[78] |
Wieland A, Patel MR, Cardenas MA, et al. Defining HPV-specific B cell responses in patients with head and neck cancer[J]. Nature, 2021, 597(7875): 274−278. doi: 10.1038/s41586-020-2931-3
|
[79] |
Pretscher D, Distel LV, Grabenbauer GG, et al. Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma[J]. BMC Cancer, 2009, 9: 292. doi: 10.1186/1471-2407-9-292
|
[80] |
DeFalco J, Harbell M, Manning-Bog A, et al. Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens[J]. Clin Immunol, 2018, 187: 37−45. doi: 10.1016/j.clim.2017.10.002
|
[81] |
Lechner A, Schlößer HA, Thelen M, et al. Tumor-associated B cells and humoral immune response in head and neck squamous cell carcinoma[J]. Oncoimmunology, 2019, 8(3): 1535293. doi: 10.1080/2162402x.2018.1535293
|
[82] |
Jeske SS, Brand M, Ziebart A, et al. Adenosine-producing regulatory B cells in head and neck cancer[J]. Cancer Immunol Immunother, 2020, 69(7): 1205−1216. doi: 10.1007/s00262-020-02535-6
|
[83] |
Meylan M, Petitprez F, Becht E, et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer[J]. Immunity, 2022, 55(3): 527−541.e5. doi: 10.1016/j.immuni.2022.02.001
|
[84] |
Lin Z, Liu L, Xia Y, et al. Tumor infiltrating CD19+ B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors[J]. Oncoimmunology, 2018, 7(10): e1477461. doi: 10.1080/2162402x.2018.1477461
|
[85] |
Yao C, Yu H, Zhou G, et al. Tumor-infiltrating plasma cells are the promising prognosis marker for esophageal squamous cell carcinoma[J]. Esophagus, 2021, 18(3): 574−84. doi: 10.1007/s10388-021-00828-y
|